Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multicenter Study of UB-VV400 With Rapamycin in Relapsed or Refractory B-cell Malignancies

NCT07735533 is registered in ClinicalTrials.gov with Umoja Biopharma as lead sponsor.

NCT NCT07735533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07735533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multicenter Study of UB-VV400 With Rapamycin in Relapsed or Refractory B-cell Malignancies
Lead sponsor
Umoja Biopharma
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
August 31, 2031
Enrollment
274 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma (dlbcl), grade 3b follicular lymphoma, high grade b cell lymphoma, lymphoma non-hodgkin, lymphoma, b cell, primary mediastinal b cell lymphoma, richter transformation lymphoma